Clinical Rheumatology

, Volume 4, Issue 2, pp 155–160 | Cite as

Short course of synacthen therapy as an adjunct in the management of rheumatoid arthritis

  • E. Ben-Chetrit
  • Y. Naparstek
  • M. Ehrenfeld
  • M. Eliakim


The effect of synthetic adrenocorticotrophic hormone (Synacthen), in conjunction with hydroxychloroquine, aurothioglucose, or pencillamine, was evaluated retrospectively in 21 patients with rheumatoid arthritis (RA). One mg of depo Synacthen was administered at increasing intervals of 4 to 14 days for a total period of 3 to 7 months. Fourteen patients with RA on either hydroxychloroquine or aurothioglucose and not on Synacthen, served as controls. Patients in the Synacthen group were, on the whole, sicker, as indicated by a lower functional capacity, higher mean erythrocyte sedimentation rate, and systemic and articular indices. Physicians' estimate of the patients condition after 1–2 months of therapy showed no improvement or deterioration in 10 out of 13 cases in the control group. Likewise, the erythrocyte sedimentation rate decreased significantly more and seronegativity was achieved in more of the Synacthen-treated cases. Six to 8 months after the beginning of therapy (1 to 4 months after cessation of Synacthen) clinical improvement was comparable in both groups, although seroconversion was more common in patients who had received Synacthen (7 out of 10 as compared to 1 out of 7 respectively). It is suggested that Synacthen may be used safely in the early phase of selected RA patients, until the effect of second-line drugs is achieved.

Key words

Rheumatoid Arthritis Synacthen 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dick, C.W., DeCeulaer, S. Nonsteroidal anti-rheumatic drugs. In: Textbook of Rheumatology, 1st edition. Editors: Kelley, W.N., Harris, E.D., Ruddy, S., Sledge, B. Philadelphia, W.B. Saunders, 1981, pp. 768–784.Google Scholar
  2. 2.
    Julkunen, H., Rokkanen, P., Laine, H. Chloroquine treatment and bone changes in rheumatoid arthritis. Scand J Rheumatol, 1976, 5, 36–38.PubMedGoogle Scholar
  3. 3.
    Sigler, J.W., Bluhm, G.B., Duncan, H., et al. Gold salts in the treatment of rheumatoid arthritis: a double-blind study. Ann Intern Med, 1974, 80, 21–26.PubMedGoogle Scholar
  4. 4.
    Hill, H.F. Treatment of rheumatoid arthritis with penicillamine. Semin Arthritis Rheum, 1977, 6, 361–388.PubMedGoogle Scholar
  5. 5.
    Bacon, P.A., Myles, A.B., Beardwell, C.G., Daly, J.R., Savage, O. Corticosteroid withdrawal in rheumatoid arthritis. Lancet, 1966, 1, 935–937.PubMedGoogle Scholar
  6. 6.
    Harris, E.D., Emkey, R.D., Nichols, J.E., Newberg, A. Low dose prednisone therapy in rheumatoid arthritis: a double blind study. J Rheumatol, 1983, 10, 713–721.PubMedGoogle Scholar
  7. 7.
    Masi, A.T. Low dose glucocorticoid therapy in rheumatoid arthritis (RA): Transitional or additional therapy? J Rheumatol, 1983, 10, 675–678.PubMedGoogle Scholar
  8. 8.
    Ropes, M.W., Bennett, E.A., Cobb, S., et al. Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis, 1958, 9, 175–176.PubMedGoogle Scholar
  9. 9.
    Steinbrocker, O., Traeger, C.H., Butterman, R.C. Therapeutic criteria in rheumatoid arthritis. JAMA, 1949, 140, 659–662.Google Scholar
  10. 10.
    Lansbury, J. Report of a three-year study on systemic and articular indexes in rheumatoid arthritis: Theoretic and clinical considerations. Arthritis Rheum, 1958, 1, 505–522.PubMedGoogle Scholar
  11. 11.
    Axelrod, L. Glucocorticoid therapy. Medicine, 1976, 55, 39–65.PubMedGoogle Scholar
  12. 12.
    Allander, E. ACTH or corticosteroid: A critical review of results and possibilities in the treatment of chronic disease. Acta Rheum Scand, 1969, 15, 277–296.PubMedGoogle Scholar
  13. 13.
    Savage, O., Copeman, W.S.C., Chapman, L., Wells, M.V. Treadwell, B.L.J. Pituitary and adrenal hormones in rheumatoid arthritis. Lancet, 1962, 232–235.Google Scholar
  14. 14.
    Nuki, G., Jasani, M., Downie, W.W., et al. Clinicopharmacological studies on depot tetracosactrin in patients with rheumatoid arthritis. Pharmacol Clin, 1970, 2, 99–108.Google Scholar
  15. 15.
    Massias, P. Indications for depot tetracosactide in rheumatology. In: A.C.T.H. — A practical review of progress to date. Editor Schuppli, R., Bern. Hans Huber Publications, 1973, pp. 168–181.Google Scholar
  16. 16.
    Donnelly, P., Cooke, D. A study of the combined effect of ACTH (gel) and D-penicillamine on the functional disability of patients with rheumatoid arthritis. J Rheumatol, 1982, 9, 867–872.PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • E. Ben-Chetrit
    • 1
  • Y. Naparstek
    • 1
  • M. Ehrenfeld
    • 1
  • M. Eliakim
    • 1
  1. 1.Department of Medicine AHadassah University HospitalJerusalemIsrael

Personalised recommendations